Successful treatment of retractile mesenteritis with oral progesterone.
Retractile mesenteritis is a rare inflammatory mesenteric disorder that involves the intestine secondarily. The natural history of this process is diverse, but most patients require some empiric therapeutic measures. Up to now, pharmacological therapy has included corticosteroids, colchicine, and immunosuppressive drugs. Although these drugs are successful in most patients, some have been refractory to these therapies and, in others, the beneficial effects were counterbalanced by adverse reactions. Many patients require surgery, but most have poor results. This report describes a 42-year-old man with histologically proven retractile mesenteritis refractory to surgical intervention who had a good response to oral progesterone (10 mg/day for 6 months) with complete disappearance of tumor mass and clinical symptoms. No adverse effects were detected. Current knowledge about the mechanism by which progesterone affects fibrogenesis is scanty. It seems likely that progesterone down-regulates proliferation and metabolism of fibroblasts and fibrogenesis.
Mazure
R
R
Clinical Department, Hospital de Gastroenterologia, Buenos Aires, Argentina.
Fernandez Marty
P
P
Niveloni
S
S
Pedreira
S
S
Vazquez
H
H
Smecuol
E
E
Kogan
Z
Z
Boerr
L
L
Mauriño
E
E
Bai
J C
JC
D000284:Administration, Oral; D000328:Adult; D006801:Humans; D007421:Intestine, Small / Q000473:pathology / Q000601:surgery; D008297:Male; D015436:Panniculitis, Peritoneal / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D011374:Progesterone / Q000627:therapeutic use*; D019233:Retreatment; D014057:Tomography, X-Ray Computed
D011374:Progesterone